Caplacizumab: First Global Approval

Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the E...

Descripción completa

Detalles Bibliográficos
Autor principal: Duggan, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280848/
https://www.ncbi.nlm.nih.gov/pubmed/30298461
http://dx.doi.org/10.1007/s40265-018-0989-0
_version_ 1783378748670738432
author Duggan, Sean
author_facet Duggan, Sean
author_sort Duggan, Sean
collection PubMed
description Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval.
format Online
Article
Text
id pubmed-6280848
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-62808482018-12-26 Caplacizumab: First Global Approval Duggan, Sean Drugs AdisInsight Report Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody(®) caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval. Springer International Publishing 2018-10-08 2018 /pmc/articles/PMC6280848/ /pubmed/30298461 http://dx.doi.org/10.1007/s40265-018-0989-0 Text en © Springer Nature 2018, corrected publication 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle AdisInsight Report
Duggan, Sean
Caplacizumab: First Global Approval
title Caplacizumab: First Global Approval
title_full Caplacizumab: First Global Approval
title_fullStr Caplacizumab: First Global Approval
title_full_unstemmed Caplacizumab: First Global Approval
title_short Caplacizumab: First Global Approval
title_sort caplacizumab: first global approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280848/
https://www.ncbi.nlm.nih.gov/pubmed/30298461
http://dx.doi.org/10.1007/s40265-018-0989-0
work_keys_str_mv AT duggansean caplacizumabfirstglobalapproval

Ejemplares similares